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PREVENTING HIV INFECTION AMONG INJECTING 
DRUG USERS IN HIGH RISK COUNTRIES
AN ASSESSMENT OF THE EVIDENCE
An estimated 13 million people worldwide inject drugs. Of those, 78 per-
cent live in developing or transitional countries. The sharing of contaminated
injecting equipment has become a major driving force of the global AIDS pan-
demic, and is the primary mode of HIV transmission in many countries
throughout Eastern Europe, the Commonwealth of Independent States, and
significant parts of Asia. In some cases, HIV is spreading rapidly from injecting
drug users to their partners through sexual transmission, and from injecting
drug users and their partners to newborns. Reversing the rise of HIV infection
among injecting drug users in these “high-risk” countries has thus become an
urgent global public health challenge—one that remains largely unmet. 
In response to this crisis, in 2005 the Joint United Nations Programme on
HIV/AIDS (UNAIDS) and the Bill & Melinda Gates Foundation commissioned
the Institute of Medicine to evaluate strategies for preventing HIV transmission
through contaminated injecting equipment. The resulting report, Preventing
HIV Infection among Injecting Drug Users in High Risk Countries, finds that sever-
al key approaches can reduce HIV related risk behavior among injecting drug
users. The report urges high-risk transitional and developing countries to take
immediate steps to make these techniques widely available. 
TREATING DRUG DEPENDENCE
Treating drug dependence is a critical strategy for preventing HIV trans-
mission. Drug treatment includes both pharmacological and psychosocial
approaches. Two primary types of pharmacotherapies are available for treating
dependence on opioids, such as heroin: agonist and antagonist medications.
Opioid agonist medications work by preventing withdrawal symptoms, cre-
atign cross-tolerance to the effects of opiates, and reducing opiate cravings—
and therefore the need to use illicit drugs. 
Strong evidence shows that two opioid agonist medications—methadone
and buprenorphine—are effective in treating dependence on opioids. Patients
can receive these medications for sustained periods. Such maintenance treat-
ment reduces illicit drug use, how often individuals inject, and also how often
they share injecting equipment. Studies also suggest that combining psychoso-
cial interventions with agonist medications may improve patient outcomes.
Drug users who remain in treatment and receive sufficient doses of the med-
ication, experience greater benefits, including protection against HIV infection. 
Methadone and buprenorphine treatment do not aim specifically to reduce
risky sexual conduct, such as unprotected sex, multiple sexual partners, and the
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trading of sex for drugs. Nor does such treatment address co-occurring use of other
drugs—common among people addicted to opioids. However, given the overall ben-
efits of opioid agonist treatment—and evidence that drug users who discontinue
treatment have high rates of re-addiction and criminal behavior—high-risk countries
should make such treatment widely available, where feasible.
Despite the many benefits of treatment with methadone or buprenorphine, these
drugs can be diverted to illicit markets. Techniques for curbing diversion—such as by
directly observing patients while they take the drugs—may increase the cost of treat-
ment and therefore limit its availability. Countries must balance the competing goals
of making treatment drugs widely available and reducing their diversion. 
Naltrexone is an alternative medication for opioid-dependent individuals who do
not want or cannot gain access to methadone and buprenorphine. Naltrexone is an
opioid antagonist: it blocks the euphoric effects of heroin and other opioids com-
pletely, and is used to help patients remain abstinent from opioids. Patients must be
detoxified before starting naltrexone. Although such therapy can be effective for some
patients, high attrition rates and limited appeal have limited its effectiveness, and it
is less likely to have a significant public health impact on opioid use or HIV trans-
mission if it is the only treatment available. 
Evidence for the effectiveness of some other abstinence-oriented treatments such
as Narcotics Anonymous and residential approaches is limited, and attrition rates are
high. However, these are important treatment options for opioid-dependent people
who cannot gain access to methadone and buprenorphine, and for people addicted to
stimulants and other classes of drugs. People who remain in treatment longer do bet-
ter on a range of outcomes. 
Unfortunately, no medications are yet available for treating addiction to stimu-
lants such as cocaine and methamphetamine. Studies in controlled settings have
shown that contingency management—a behvioral therapy in which patients who
remain drug-free receive cash or other rewards—is effective in treating people
dependent on stimulants. However, the real-world practicality of this approach is less
clear. Although other psychotherapeutic approaches may be effective and are
improtant treatment options, the need to develop and evaluate better treatments for
stimulant dependence is urgent. 
PROVIDING CLEAN NEEDLES AND SYRINGES 
Avenues for making clean injecting equipment more widely available—and thus
reducing drug-related HIV risk—include needle and syringe exchange; the legal and
economical sale of needles and syringes through pharmacies, voucher schemes,
physician prescription programs, and vending machines; supervised injecting facili-
ties; and disinfection programs. 
Needle and syringe exchange is usually one part of multi-component HIV pre-
vention programs. Such programs may also provide condoms and education on dis-
infection, and refer them to drug abuse treatment and other services. Multi-compo-
nent HIV prevention programs that include sterile needle and syringe access are
effective in reducing drug related HIV risks such as needle and syringe sharing.
Undiluted bleach can inactivate HIV on injecting equipment in the laboratory,
and in the field if used according to guidelines. However, in practice, injecting drug
users do not use bleach correctly, so programs that distribute bleach should also edu-
cate drug users on proper techniques. In some countries, bleach is not available or
acceptable, and it may be necessary to use other disinfectants. Drug users should rely
on such methods only when they cannot stop injecting, or when they do not have
access to new equipment.
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As with drug treatment, a common concern is that sterile needle and syringe
access may produce unintended results, including more new drug users, expanded
networks of high-risk users, more frequent injection, and more discarded needles in
the community. However, studies do not find evidence of such outcomes. 
Sterile needle and syringe access can prove important in linking drug users to
health and social services. Such programs also have the potential to help prevent hep-
atitis C—which is transmitted more readily by injection drug use than HIV—by pro-
viding other sterile injecting equipment, such as cotton swabs and alcohol wipes.
Although questions remain about the impact of multi-component programs that
include sterile needle and syringe access on actual HIV incidence, the report recom-
mends that high-risk countries act now to implement such programs. These programs
should include multiple access points and methods of delivery, focus on reducing sex-
ual risks, and actively refer drug users to other services. 
OUTREACH AND EDUCATION
Outreach-based efforts to prevent HIV transmission—which may direct drug
users to needle and syringe exchange, for example—have helped reduce drug-related
risk behavior, including injection frequency and sharing of injection equipment.
Outreach is effective in linking hard-to-reach injecting drug users with drug treatment
and other health and social services. The impact of outreach on sex-related HIV risk
behavior is less clear. High-risk countries should make outreach an important part of
multi-component programs used to prevent HIV among injecting drug users, and to
link hard-to-reach groups with medical and social services. 
OVERCOMING BARRIERS TO REDUCING HIV RISK
Individual and structural—or environmental—factors influence HIV risk among
injecting drug users, and can facilitate or undermine efforts to prevent transmission.
One of the most important is tension between criminal justice and public health
approaches. For example, drug users often fail to participate in HIV prevention pro-
grams because they fear arrest. To address this tension, nations should take steps to
better align law enforcement and public health approaches. 
Social stigma and discrimination—even among medical professionals—also
affect whether drug users seek HIV prevention services, and the availability of those
services. To address this, countries should tailor their HIV prevention efforts to local
cultures and coordinate them with key stakeholders, including government agencies,
law enforcement, and religious and civil society groups. 
Limited public health infrastructure can further hamper efforts to scale up HIV
prevention programs among injecting drug users—especially methadone and
buprenorphine treatment. Many countries will need to expand the number of clinics
and training for treatment providers and other professionals. Efforts to improve the
infrastructure for HIV prevention among injecting drug users can build upon the
global scale-up of infrastructure for treating and preventing HIV/AIDS more gener-
ally. Yet individual countries must also consider how best to use scarce funds to pre-
vent HIV transmission among drug users. Careful forethought is critical because sus-
taining the gains from such programs requires stable funding. 
Research and experience show that HIV prevention programs targeting injecting
drug users can work, and high-risk countries should act now to implement them.
However, these countries need to monitor and evaluate their programs from the start
to ensure their effectiveness, given that most evidence now stems from studies in
resource-rich countries. 3
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FOR MORE INFORMATION…
Copies of Preventing HIV Infection among Injecting Drug Users in High Risk Countries are available
from the National Academies Press, 500 Fifth Street, N.W., Lockbox 285, Washington, DC 20055; (800)
624-6242 or (202) 334-3313 (in the Washington metropolitan area); Internet, http://www.nap.edu.  The
full text of this report is available at http://www.nap.edu.
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